Glide Pharma signs biologicals deal with major pharma company
Glide Pharma has signed an agreement with a pharmaceutical company to evaluate its proprietary Glide SDI(tm) - Solid Dose Injector - technology for the delivery of a branded peptide product. This is Glide Pharma's third deal involving a biological product, with further agreements close to fruition.
The deal is described as a future-directed relationship, focusing initially on one of the pharma company's branded biologicals; the new partner has also taken an option to enter into a full development programme. Under the terms of the deal, Glide Pharma will develop and test a range of solid dosage formulations of the branded peptide in the unique Glide SDI. These formulations will then be supplied to the partner company for further evaluation.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.